Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthmaTools Sandham, David A. and Barker, Lucy and Brown, Lyndon and Brown, Zarin and Budd, David and Charlton, Steven J. and Chatterjee, Devnanden and Cox, Brian and Dubois, Gerald and Duggan, Nicholas and Hall, Edward and Hatto, Julia and Maas, Janet and Manini, Jodie and Profit, Rachael and Riddy, Darren and Ritchie, Catherine and Sohal, Bindi and Shaw, Duncan and Stringer, Rowan and Sykes, David A. and Thomas, Matthew and Turner, Katherine L. and Watson, Simon J. and West, Ryan and Willard, Elisabeth and Williams, Gareth and Willis, Jennifer (2017) Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthma. ACS Medicinal Chemistry Letters, 8 . pp. 582-586. ISSN 1948-5875 Full text not available from this repository.AbstractFurther optimization of an initial DP2 receptor antagonist clinical candidate NVPQAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2- (trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compound 11, NVP-QAW039, fevipiprant), which exhibits improved potency on human eosinophils and Th2 cells, together with a longer receptor residence time, and is currently in clinical trials for severe asthma.
Actions (Archive Staff Only)
|
From the 1st Oct 2021, the research publications and student eTheses of University of Nottingham Ningbo China authors will be handled through the UNNC Research Information System (RIS).
If you are a UNNC author, please login to the UNNC RIS in order to deposit articles and etheses after this date, or contact UNNCRIS@nottingham.edu.cn if you have any enquiries in regard to this change.
If you are a UNNC author, please login to the UNNC RIS in order to deposit articles and etheses after this date, or contact UNNCRIS@nottingham.edu.cn if you have any enquiries in regard to this change.
Tools
Tools
